Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Mitchell, SD
NPI: 1013983352Primary Practice Location
AVERA QUEEN OF PEACE
HQ Phone
Get M.D. Vinod's Phone Numberphone_androidMobile
Get M.D. Vinod's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardSD State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 191 | 343 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 189 | 229 |
| 3 | 38222Bone marrow biopsy and aspiration | 34 | 42 |
| 4 | 99212Established patient outpatient visit, total time 10-19 minutes | 33 | 34 |
| 5 | 99152Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 15 minutes | 30 | 38 |
Authors: Edmund Waller, Muna Qayed, Peter Holman, Gary Myers
Journal: Cytotherapy
Publication Date: 2022-06-17
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Authors: Salman Fazal, Ruben Mesa, Ryan Mattison, Abdulraheem Yacoub
Publication Date: 2024-09
Lead Sponsor: Incyte Corporation
Intervention / Treatment: DRUG: Ruxolitinib
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Lenalidomide, DRUG: Dexamethasone, OTHER: Quality-of-Life Assessment, DRUG: Bortezomib, BIOLOGICAL: Daratumumab and Hyaluronidase-fihj
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, DRUG: Lenalidomide, DRUG: Dexamethasone, OTHER: Quality-of-Life Assessment, BIOLOGICAL: Daratumumab